FIGURE 4. Pathway deregulation in breast cancer cell lines predicts drug sensitivity.
From the following article:
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Andrea H. Bild, Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, David Harpole, Johnathan M. Lancaster, Andrew Berchuck, John A. Olson, Jr, Jeffrey R. Marks, Holly K. Dressman, Mike West & Joseph R. Nevins
Nature 439, 353-357(19 January 2006)
doi:10.1038/nature04296
a, Pathway predictions in breast cancer cell lines. The results plotted show the predicted probability of pathway activation (red indicates high probability; blue indicates low probability). b, Sensitivity to pathway-specific drugs. Top: cells were treated with 3.75 
M of farnesyltransferase inhibitor (L-744,832) for 96 h. Proliferation was assayed using a standard MTS tetrazolium colorimetric method. The degree of proliferation inhibition was plotted as a function of probability of Ras pathway activation as determined in a. Middle: same as for the top panel but using FTS (200 M). Bottom: same as for the top panel but using the Src pathway inhibitor SU6656 (1.5 M), and with the degree of proliferation inhibition plotted as a function of Src pathway activation.
